Sumavel Dosepro is a drug owned by Endo Operations Ltd. It is protected by 16 US drug patents filed from 2013 to 2014. Out of these, 3 drug patents are active and 13 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 22, 2026. Details of Sumavel Dosepro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7776007 | Device for readying a needle free injector for delivery |
Nov, 2026
(1 year, 11 months from now) | Active |
| US7901385 | Casing |
Jul, 2026
(1 year, 7 months from now) | Active |
| US8241243 | Needleless injector drug capsule and a method for filling thereof |
Dec, 2025
(1 year, 6 days from now) | Active |
| US8287489 | Device for readying a needle free injector for delivery |
Dec, 2024
(12 days ago) |
Expired
|
| US8118771 | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(1 year, 4 months ago) |
Expired
|
| US8267903 | Casing |
Mar, 2023
(1 year, 9 months ago) |
Expired
|
| US8491524 | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(2 years ago) |
Expired
|
| US8241244 | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(2 years ago) |
Expired
|
| US8343130 | Needleless injector |
Oct, 2022
(2 years ago) |
Expired
|
| US6280410 | Method of filling a drug capsule and article produced thereby |
Mar, 2017
(7 years ago) |
Expired
|
| US6135979 | Spring-powered dispensing device for medical purposes |
Mar, 2017
(7 years ago) |
Expired
|
| US6251091 | Needleless injector drug capsule and filling method |
Dec, 2016
(8 years ago) |
Expired
|
| US5957886 | Spring-Powered dispensing device |
Mar, 2016
(8 years ago) |
Expired
|
| US6174304 | Filling device for a needless injector cartridge |
Dec, 2015
(9 years ago) |
Expired
|
| US6681810 | Filling device for a needleless injector cartridge |
Dec, 2015
(9 years ago) |
Expired
|
| US5891086 | Needle-less injector |
Jul, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sumavel Dosepro's patents.
Latest Legal Activities on Sumavel Dosepro's Patents
Given below is the list of recent legal activities going on the following patents of Sumavel Dosepro.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 30 Aug, 2021 | US8491524 |
| Maintenance Fee Reminder Mailed Critical | 15 Mar, 2021 | US8491524 |
| Expire Patent Critical | 08 Feb, 2021 | US8343130 |
| Expire Patent Critical | 23 Nov, 2020 | US8287489 |
| Expire Patent Critical | 26 Oct, 2020 | US8267903 |
| Expire Patent Critical | 21 Sep, 2020 | US8241244 |
| Expire Patent Critical | 21 Sep, 2020 | US8241243 |
| Maintenance Fee Reminder Mailed Critical | 24 Aug, 2020 | US8343130 |
| Maintenance Fee Reminder Mailed Critical | 08 Jun, 2020 | US8287489 |
| Maintenance Fee Reminder Mailed Critical | 11 May, 2020 | US8267903 |
US patents provide insights into the exclusivity only within the United States, but Sumavel Dosepro is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sumavel Dosepro's family patents as well as insights into ongoing legal events on those patents.
Sumavel Dosepro's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sumavel Dosepro's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 22, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sumavel Dosepro Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Sumavel Dosepro. 29 different companies have already filed for the generic of Sumavel Dosepro, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Sumavel Dosepro's generic
Alternative Brands for Sumavel Dosepro
There are several other brand drugs using the same active ingredient (Sumatriptan Succinate) as Sumavel Dosepro. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Currax |
| ||
| Meridian Medcl |
| ||
| Teva Branded Pharm |
| ||
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Sumavel Dosepro's active ingredient. Check the complete list of approved generic manufacturers for Sumavel Dosepro
About Sumavel Dosepro
Sumavel Dosepro is a drug owned by Endo Operations Ltd. Sumavel Dosepro uses Sumatriptan Succinate as an active ingredient. Sumavel Dosepro was launched by Endo Operations in 2013.
Approval Date:
Sumavel Dosepro was approved by FDA for market use on 26 November, 2013.
Active Ingredient:
Sumavel Dosepro uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Dosage:
Sumavel Dosepro is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |